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Modeling T cell receptor recognition of CD1-lipid
and MR1-metabolite complexes
Brian G Pierce1,2*, Thom Vreven1 and Zhiping Weng1*
Abstract
Background: T cell receptors (TCRs) can recognize diverse lipid and metabolite antigens presented by MHC-like
molecules CD1 and MR1, and the molecular basis of many of these interactions has not been determined. Here
we applied our protein docking algorithm TCRFlexDock, previously developed to perform docking of TCRs to
peptide-MHC (pMHC) molecules, to predict the binding of αβ and γδ TCRs to CD1 and MR1, starting with the
structures of the unbound molecules.
Results: Evaluating against TCR-CD1d complexes with crystal structures, we achieved near-native structures in the top
20 models for two out of four cases, and an acceptable-rated prediction for a third case. We also predicted the structure
of an interaction between a MAIT TCR and MR1-antigen that has not been structurally characterized, yielding a
top-ranked model that agreed remarkably with a characterized TCR-MR1-antigen structure that has a nearly identical
TCR α chain but a different β chain, highlighting the likely dominance of the conserved α chain in MR1-antigen
recognition. Docking performance was improved by re-training our scoring function with a set of TCR-pMHC
complexes, and for a case with an outlier binding mode, we found that alternative docking start positions improved
predictive accuracy. We then performed unbound docking with two mycolyl-lipid specific TCRs that recognize
lipid-bound CD1b, which represent a class of interactions that is not structurally characterized. Highly-ranked
models of these complexes showed remarkable agreement between their binding topologies, as expected based
on their shared germline sequences, while differences in residue-level interactions with their respective antigens
point to possible mechanisms underlying their distinct specificities.
Conclusions: Together these results indicate that flexible docking simulations can provide accurate models and
atomic-level insights into TCR recognition of MHC-like molecules presenting lipid and other small molecule antigens.
Keywords: TCR, MAIT, CD1d, CD1b, GEM, MHC-like
Background
T cell receptors (TCRs) display remarkable versatility in
their ability to specifically recognize a wide array of struc-
turally and chemically diverse antigens. This is highlighted
by a number of studies showing that, in addition to
well-characterized recognition of peptide-major histo-
compatibility complex (pMHC) [1], many TCRs engage
MHC-like molecules CD1, which present a variety of
lipid antigens [2], and MR1, which presents vitamin B
metabolites [3]. At the sequence level, these TCRs can
be restricted or diverse in their germ-line chain usage,
depending in part on the T cell type, antigen, and
antigen-presenting molecule [2].
The understanding of the molecular basis of TCR in-
teractions with CD1 and MR1 has been greatly advanced
by a number of crystallographic studies that have eluci-
dated the interface sites, key contacts, and binding
modes of several of these complexes. This includes type
I and type II natural killer T cell (NKT) TCR interactions
with CD1d-lipid [4-6], mucosal-associated invariant T
cell (MAIT) TCR interfaces with unliganded [7] and
ligand-bound MR1 [8], and recent studies of two γδ
TCRs bound to CD1d-lipid [9,10]. While these have pro-
vided a clear view of the antigen recognition underlying
several of the invariant and diverse T cell subsets, owing
to their variety and the effort required in experimental
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structure determination, the crystal structures of a num-
ber of key complexes have not yet been solved.
Here we describe the adaptation of the TCR docking
algorithm, TCRFlexDock, previously shown to produce
highly accurate TCR-pMHC structural predictions [11],
to predict complexes of TCRs with CD1 and MR1 with
antigen (Ag). We assessed unbound docking perform-
ance using four known structures of TCRs with CD1d,
showing that for most cases accurate models were pro-
duced. We also predicted the complex between a MAIT
TCR and MR1-Ag, an interaction that has not yet been
structurally described, and assessing models against a re-
lated MAIT TCR bound to MR1-Ag, found strong agree-
ment between predicted complex and the likely conserved
binding mode. Applying TCRFlexDock to predict the
structure of two germline-encoded, mycolyl lipid-reactive
(GEM) TCRs bound to CD1b, we produced models that
provide insight into both their shared sequence features
and distinct antigen specificities.
Results
Prediction of TCR-CD1d and TCR-MR1 complexes
Searching for existing unbound and bound TCR and
MHC-like protein structures in the Protein Data Bank
(PDB) [12], we identified four TCR-CD1d-Ag test cases
(Table 1) representing various classes of TCRs (Type I
NKT TCR, Type II NKT TCR, and two γδ TCRs). Add-
itional complexes of the same class with essentially identi-
cal docking orientations (e.g. Type I NKT TCRs bound to
CD1d and other antigens) were not included. We also
identified a case with an unbound MAIT TCR (TRAV1-2-
TRAJ33-TRBV20 germ line) that binds MR1 presenting
the antigen 6FP (6-formyl pterin, a vitamin B metabolite),
with a nearly identical sequence to the α chain from a
structure of another MAIT TCR (TRAV1-2-TRAJ33-
TRBV6 germ line) bound to MR1-6-FP (Table 1); two resi-
dues are substituted near the N-term of the CDR3α loop.
Given the likely “common mode of MAIT TCR-MR1
docking” [13], supported by additional MAIT TCR com-
plexes with bovine MR1 and TRBV6 TCR variants [14],
we evaluated docking predictions of the unbound TRBV20
MAIT TCR to MR1-6FP using the conserved α chain and
MR1 in the bound structure, to determine whether the α
chain binding conformation is recapitulated by docking,
and to predict how the distinctive TRBV20 chain engages
MR1-Ag. Collectively, these TCR-CD1d-Ag and TCR-MR1-
Ag structures represent a wide variety of docking modes
(Figure 1), with greater variability than the TCR-pMHC
complexes we considered in our previous work [11].
We performed flexible protein docking using TCRFlex-
Dock to predict the complexes in Table 1 using the un-
bound TCR and CD1d-Ag/MR1-Ag structures; results are
shown in Table 2, with test cases represented by their
complex PDB IDs from Table 1. Scores versus interface
root-mean-square distances (RMSDs) for cases with hits
are shown in Figure 2. We assessed models using CAPRI
criteria [21], classifying them as incorrect, acceptable,
medium accuracy, or high accuracy, and defined hits, as in
our previous study of TCR-pMHC docking [11], as those
with medium or high accuracy. For two out of the four
CD1d test cases in Table 1 (4EI5 and 4LHU), hits were
identified in the top 20 predictions, ranked as in our previ-
ous work by ZRANK 2 (ZR2). For test case 4MNG (γδ
TCR-CD1d-sulfatide), relatively few hit predictions were
generated, and these were not well-ranked (the top hit was
ranked 235). Despite its rigid-body classification due to
minimal binding conformational changes, this case was
challenging due to its atypical docking orientation featur-
ing only the δ TCR chain contacting CD1d-sulfatide [10],
resulting in a significant distance from the docking start
position as well as a smaller interface area which is un-
favorable for the docking scoring function. However, near-
hits (acceptable predictions; in parentheses in Table 1)
were highly ranked for this case, with a top rank of 10. For
test case 3HUJ, no hits were found among the 1000
TCRFlexDock models, which was likely due to its outlier
binding mode and distance from the starting docking
orientation (over 20 Å ligand RMSD). Performance in this
case was improved by employing alternative docking start
sites closer to its bound orientation, as noted below.
For the MAIT TCR-MR1-6FP case, the predictions were
remarkably consistent with a conserved MAIT TCR α
Table 1 The TCR-CD1d-Ag and TCR-MR1-Ag test cases
PDB code
Complex TCR Ligand TCR name TCR type Ligand name Binding RMSD1, Å Difficulty2
3HUJ [15] 2EYS [16] 1ZT4 [17] NKT15 Type I NKT CD1d-α-GalCer 1.04 Rigid
4EI5 [5] 4EI6 [5] 2AKR [18] XV19 Type II NKT CD1d-sulfatide 1.08 Medium
4LHU [9] 4LFH [9] 1ZT4 [17] 9C2 γδ CD1d-α-GalCer 0.90 Rigid
4MNG [10] 4MNH [10] 4MQ7 [10] DP10.7 γδ CD1d-sulfatide 0.68 Rigid
4L4T [8]3 4DZB [19]3 4GUP [3] MAIT MAIT MR1-6FP 0.87 Rigid
1Backbone atom root-mean-square distance between interface residues in the bound structure and corresponding residues in the unbound structures.
2Docking difficulty, based on extent of binding conformational changes [20].
3The bound and unbound MAIT TCRs are closely related, with nearly identical α chains; the differing β chains (TRBV6 in 4L4T and TRBV20 in 4DZB) were excluded
from RMSD calculations and evaluation of docking predictions.
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chain binding conformation, with the top-ranked model
involving the TRBV20 TCR classified a hit with respect to
the bound crystal structure with the TRBV6 TCR, and the
third-ranked model having the lowest RMSD (1.07 Å)
from the bound structure among all docking models. This
model, shown in Figure 3, exhibits nearly perfect matches
with TCRα backbone and key side chains in the crystal
structure (e.g. hot spot TCR residue Y95α). In contrast,
the modeled TRBV20 and crystal structure TRBV6 chains
differ somewhat in CDR loop structure and overall orien-
tation. This is consistent with CDR3β swapping experi-
ments between the TRBV20 and TRBV6 MAIT TCRs
considered here that ablated MR1-Ag binding, which im-
plied a TRBV germline context dependence for CDR3β
loops (“possibly via steric hindrance mechanisms”) [19].
Furthermore there are relatively few favorable side chain
contacts between modeled TRBV20 β chain and MR1, in
agreement with alanine scanning mutagenesis data [19]
that found no individual β chain CDR mutants of this
MAIT TCR that significantly altered MR1 recognition.
To investigate whether the TCR CDR loop backbone
structure had a significant relationship with overall
docking accuracy for these cases, we compared RMSD
for modeled versus bound TCR residue backbone atoms
(for the subset of TCR residues within 10 Å of CD1-Ag)
with rigid-body ligand RMSD for the 1000 docking
models of two test cases (Additional file 1: Figure S1).
Surprisingly, there was little relationship between these
values, indicating that although a bound-like TCR back-
bone will improve the hit rate of the docking simulation
as we previously noted [11], the sampling of CDR loop
conformations during docking includes bound-like con-
formations for both hits and non-hits, and a near-native
docking position (i.e. low ligand RMSD) does not neces-
sarily lead to accurately-modeled CDR loops.
Retraining the TCRFlexDock scoring function
We re-trained the ZRANK scoring function using the
previously reported set of TCR-pMHC test cases and
docking results [11] to determine whether such an
Figure 1 The structures and starting position of the docking test cases. Bound structures of (A) 3HUJ, (B) 4EI5, (C) 4L4T, (D) 4LHU, (E) 4MNG,
as well as a representative docking start position (F) are shown (test case 3HUJ), with TCRs colored blue (α chain) and gold (β chain), CD1 and MR1
green, and antigens magenta. Not shown are TCR constant domains, as well as the α3 domain and β2m of CD1d and MR1.
Table 2 The predictive docking performance starting from the “start1” site
Start RMSD, Å
Test case Ligand Interface Hits1 ZR2 Rank2 ZRT Rank2 T20 RMSD3, Å
3HUJ 21.23 9.67 0 - - 7.91
4EI5 8.95 3.43 7 6 1 2.21
4LHU 8.22 2.42 45 17 8 1.97
4MNG 13.9 5.06 6 235 (10) 107 (8) 3.22
4L4T4 5.77 2.63 38 1 1 1.07
1Number of hit predictions among the 1000 models from TCRFlexDock.
2Rank of the first hit; for 4MNG, values in parentheses denote the ranks of the first “acceptable” prediction.
3Lowest interface root mean square distance from bound in the top 20 predictions, ranked by the ZRT scoring function.
4Only TCR α chain and MR1 were used to evaluate these predictions, as unbound and bound TCR β chains differ in sequence.
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optimized function would improve success on the TCR-
CD1 and TCR-MR1 cases in Table 1. The re-weighted
function we derived (named ZRT, for ZRANK TCR) in-
deed led to improved predictive performance in Table 2;
though the first hit for case 4MNG was still ranked rela-
tively low, its rank improved (rank 107, versus 235 for
ZR2), while the near-hit was ranked 8 by ZRT (versus 10
by ZR2). The new TCR-pMHC derived weights had a
lower van der Waals attractive weight relative to the other
terms compared with the previous ZRANK function [22],
likely due to the lower shape complementarity of TCR-
pMHC interactions versus protein-protein interfaces in
general [23]. The top-ranked ZRT prediction for test case
4EI5 had a 2.21 Å interface RMSD from native; its struc-
ture is shown in Additional file 2: Figure S2. Despite some
deviations of the sulfatide antigen head group and CDR3β
with respect to the complex crystal structure, the XV19
TCR variable domains as a whole, as well as several key
interface side chains, are positioned similarly to those of
the known complex.
Utilizing alternate docking start sites
Considering the distinct binding orientation of the Type
I NKT TCR test case 3HUJ (Figure 1), we initialized sep-
arate docking simulations, in addition to the original
“start1” docking start site, from two alternative sites
closer to the bound orientation to determine whether
they would lead to TCRFlexDock hits. We employed a
“start2” site that was approximately equidistant from the
3HUJ and 4MNG bound orientations, with a 20 Å trans-
lational shift along the CD1d helices from “start1” (see
Methods), as well as a “fit” site that entailed root-mean-
Figure 2 Binding funnels of TCR-CD1d and TCR-MR1 test cases. Scores from ZRANK 2 (ZR2) versus interface RMSDs are given for (A) 4EI5,
(B) 4LHU, (C) 4MNG, and (D) 4L4T, with only residues from the α chain and MAIT being used to calculate interface RMSD for (D).
Figure 3 Predictions of the MAIT TCR-MR1 complex compared with crystal structure of complex with related MAIT TCR. Shown are the
(A) complex, (B) close-up of the α chain interface with MR1-Ag, and (C) close-up of the β chain interface with MR1-Ag, with selected residues
show as sticks. Predicted TCR is blue (α chain) and salmon (β chain), TCR from crystal structure (PDB code 4L4T) is gray (α chain) and orange
(β chain), MR1 is green, and 6-formyl pterin antigen is magenta. Structures were superposed by MR1 helices.
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square fitting the unbound TCR to the bound TCR pos-
ition (Figure 4). Despite substantial distance from the
bound orientation (13.65 Å ligand RMSD), docking from
the start2 site led to highly ranked hits using both ZR2
and ZRT scoring functions for 3HUJ (top hits ranked 10
and 8, respectively; Additional file 3: Table S1), though
some non-hits from start1 docking ranked higher than
these hits (Figure 4). Hits were not improved for test
case 4MNG, indicating as noted above that the interface
characteristics rather than the docking orientation alone
likely caused the docking search to yield few favorable
hits. As expected from their relatively large distances to
the bound conformation (>18 Å ligand RMSD), for the
remaining three cases the start2 docking start site led to
no hits (Additional file 3: Table S1). When pooling re-
sults from start1 and start2 sites however, the near-
native predictions were predominantly scored better by
ZRT for all these cases (Additional file 4: Figure S3). For
one test case (4LHU) we also tested pooling results from
two additional start sites (one intermediate site between
start1 and start2, and an extreme start site past start2),
and ZRT continued to rank the near-native models best
(Additional file 5: Figure S4).
Prediction of TCR complexes with CD1b-GMM and CD1
b-MA
Recently the unbound crystal structures of two clones of
germline mycolyl-lipid reactive (GEM) αβ TCRs were re-
ported [24]: clone 18 (PDB code 4G8E), which binds
CD1b-MA, and clone 42 (PDB code 4G8F) which binds
CD1b-GMM. As the complex structures have not been
reported, and the structure of CD1b-GMM was reported
in a previous study [25], we used TCRFlexDock to pre-
dict these two structures representing this class of inter-
actions. As the α chains are nearly identical between the
two GEM TCR clones and likely dominate the interac-
tions with CD1b-Ag [24], we computed the distances be-
tween the models ranked in the top 20 by ZRT for the
two TCRs based on the RMSDs between their germline
CDRα loop positions (with CD1b superposed; Additional
file 6: Figure S5). We found that the 4G8E and 4G8F
models (for brevity, we refer to unbound TCR PDB
codes to represent these two complexes) were highly
similar to each other, with many of the top 20 models
less than 4 Å apart. 4G8E model 3 and 4G8F model 12
exhibited the highest similarity in germ line CDRα posi-
tioning (1.37 Å RMSD) over CD1b-Ag, and fell into the
largest cluster of models in both sets of top 20 predic-
tions (the bottom left cluster in Additional file 7: Figure
S6). On this basis, as well as notable contacts with anti-
gen as described below, we selected these models for
further analysis.
The structures of these models (Figure 5) provide a view
of their overall recognition mode as well as several diffe-
rences in TCR contacts mediating differential antigen
recognition. GEM TCR engagement of CD1b is similar
to characterized structures of αβ TCR recognition of
pMHCs, including the murine Yae62 TCR bound to H-2
Kb and peptide (Additional file 7: Figure S6 and Figure 5A).
Closer examination of the modeled interfaces shows key
roles for certain TCR residues in mediating antigen re-
cognition, for instance Tyr31β is positioned close to the
antigen in both complexes. Arg107β of the 4G8E TCR is
of particular interest, due to its potential electrostatic
Figure 4 Binding funnels of the 3HUJ Type I NKT TCR test case. ZRANK TCR (ZRT) scores versus interface RMSDs are shown for TCRFlexDock
simulations starting from the “start1” TCR start position (red circles), “fit” TCR start position (green squares), and shifted “start2” start position
(blue triangles).
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interaction with the negatively charged head group of the
MA antigen (Figure 5B); this residue was also highlighted
based on the unbound clone 18 structure as it represented
a notable difference between the two clones’ CDR3 ar-
chitectures [24]. While these models provide a likely
mechanism of CD1b-Ag engagement, other sets of
4G8E and 4G8F models were identified that shared
docking orientations with TCR-pMHC and MAIT-
MR1-Ag interfaces (Additional file 7: Figure S6 and
Additional file 8: Figures S7).
Discussion
We have demonstrated that our TCR docking algorithm,
TCRFlexDock, is capable of producing accurate models of
TCRs recognizing MHC-like molecules presenting a variety
of non-peptide ligands. By retraining our scoring function,
we were able to improve the re-ranking performance for
test cases representing this class of complexes. Further im-
provements, for instance to improve the ranking of hits for
the 4MNG or 3HUJ cases and performance using pooled
results from alternate docking start sites, could potentially
be achieved through inclusion of other terms (e.g. long-
range partial charge rather than full charge electrostatics),
and further optimization of the pair potential parameters
and antigen atom typing. Additionally, though antigen bond
torsion angles were minimized during Rosetta docking sim-
ulations, explicit inclusion of lipid head group rotamers
(based on pre-generated conformers) could represent an-
other route for improving docking performance.
We report models of CD1b-bound GEM TCRs from
TCRFlexDock that account for a likely shared docking
orientation as well fine differences in antigen recogni-
tion. The docking searches for these cases were focused
on the CD1b site analogous to the pMHC interface en-
gaged by most TCRs; while outlier TCR binding modes
have been observed for some non-MHC ligands [26] and
would reduce change of docking success (as seen for test
case 3HUJ), mutagenesis evidence strongly suggests that
TCRs engage CD1b-Ag with a footprint similar to TCR-
pMHC interactions [27]. Two previously reported TCR-
CD1b-Ag modeling attempts (using other TCR clones)
were based on homology with TCR-pMHC complex
structures [25,28], rather than a flexible docking search;
notably, in one of these studies the TCR loops exhibited
considerable clash with antigen in the modeled com-
plexes [25], a challenge that is explicitly addressed dur-
ing the conformational search of TCRFlexDock. Within
our set of TCR-CD1b-Ag models, the dominant cluster
was similar to the Class I MHC-bound Yae62 TCR
(Figure 5 and Additional file 7: Figure S6). However, we
did identify alternative models, including several that were
similar to the TRBV6 MAIT TCR-MR1-Ag and ELS4
TCR-HLA-peptide complexes. As noted by others [24],
the MAIT, ELS4 and GEM TCRs share TRAV1-2 genes
and the former two exhibit similar docking orientations
over their respective ligands [8], yet given the structural
and residue-level differences between CD1b, MR1 and
MHC, there is a significant possibility that TCR-CD1b-Ag
interactions exhibit a distinct binding conformation, as we
identified using TCRFlexDock. Experimental structural
characterization of GEM TCR-CD1b-Ag complexes will
allow determination of which models are most accurate.
While this manuscript was under review, the x-ray
structure of a TRBV20-containing MAIT TCR (corre-
sponding to the unbound TCR we used for test case
4L4T) in complex with MR1 and antigen was reported
[29]. Though the antigens of our docking simulation
and the solved structure are not identical (thus prevent-
ing an analysis of native contacts and hits), we evaluated
interface backbone RMSD between our models and the
solved structure (PDB id 4PJ8), and the top-ranked
model by ZRT score indeed had a low interface RMSD
with respect to the experimentally determined complex
structure (1.68 Å; Additional file 9: Figure S8).
Conclusions
These updates to the TCRFlexDock algorithm, as well as
the docking test cases we assembled, represent an advance
Figure 5 Predictions of GEM TCR complexes with CD1b-Antigen. (A) GEM TCR models bound to CD1b-Ag and Yae62 TCR bound to H-2
Kb-peptide (PDB code 3RGV). Colors are: GEM α chains, blue; GEM β chains, salmon; Yae62 α chain, cyan; Yae62 β chain, yellow; CD1b/MHC, green;
antigens MA/GMM/peptide, magenta. (B) Clone 18 GEM TCR modeled interface with CD1b-MA. (C) Clone 42 GEM TCR modeled interface with
CD1b-GMM. For (B) and (C), key TCR side chains contacting antigen head group and inter-atomic distances are indicated.
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in modeling TCR-ligand recognition, extending capabil-
ities beyond TCR-pMHC modeling methods reported by
ourselves [11] and others [30,31] to modeling complexes
with lipid and metabolite antigens presented by MHC-like
molecules. Our models of MAIT TCR-MR1-Ag and GEM
TCR-CD1b-Ag complexes, which have not been described
crystallographically, provide likely mechanisms of ligand
engagement by these TCRs, and highlight the ability of ad-
vanced protein docking algorithms to complement experi-
mental techniques in probing the structural basis of
molecular recognition. These methods can be applied to
model other TCRs bound to MHC-like ligands, as more of
these interactions and TCRs become characterized, such
as a γδ TCR clone that was recently found to engage the
endothelial protein C receptor [32].
Methods
Input structures and TCR docking
TCR docking test cases were identified based on identical
sequences between TCRs and ligands from unbound and
bound PDB entries. Lipid and metabolite antigens were
also evaluated for unbound and bound structural matches.
For test case 4LHU, the lipid molecules were not identical
(JLS for the bound CD1d-α-GalCer, AGH for the un-
bound CD1d-α-GalCer) but this was due to differences in
buried hydrocarbon chains, while the exposed head
groups were the same. Prior to docking, missing unbound
TCR CDR loop residues were added to PDB files 4LFH
(test case 4LHU), 4MNH (test case 4MNG), 4G8E, and
4G8F using Modeller [33], keeping the remainder of the
TCR fixed. The unbound CD1b-MA structure was gener-
ated by truncation of the GMM antigen in the unbound
CD1b-GMM structure (PDB code 1UQS).
Flexible TCR docking was performed in the same man-
ner as presented previously [11], using a modified version
of RosettaDock to generate 1000 docking models starting
with unbound structures in a predetermined starting
orientation (described in more detail below), followed by
re-scoring docking models using ZRANK. RosettaDock
simulations were performed using an iterative procedure
(written with RosettaScripts) where the CDR3 loops
undergo a perturbation using the kinetic closure (KIC)
loop modeling protocol in Rosetta, followed by Monte
Carlo-based sampling of local rigid-body docking orienta-
tion, side chain rotamer optimization, and two rounds of
KIC refinement of all CDR loops. Parameters for lipid and
antigens were generated using Open Babel [34] to convert
from PDB to Mol2 format, followed by conversion to
Rosetta parameter files using the molfile_to_params.py
script [35]. This process was also used to determine anti-
gen torsion angles that were minimized by Rosetta during
the docking process. Docking was performed on a Linux
cluster with 2.8 GHz AMD Opteron cores; producing 50
docking models on a single core (20 such jobs were run in
parallel for each test case) took approximately 10 hours
on average (12 minutes per model). For ZRANK, antigen
partial charge parameters were obtained from polar
hydrogen Mol2 files from Open Babel, while IFACE and
ACE atom types were assigned based on congruence with
amino acid atoms.
Initial and alternate docking input positioning
As with our previous TCR docking study, for initial
docking start position (corresponding to the “start1”
site), TCRs were aligned with pseudo-symmetric axis
perpendicular to the plane of the MHC-like helices, po-
sitioned over the MHC-like helix centroid at a distance
of 25 Å, with a 45° crossing angle. We also tested an al-
ternate “start2” docking start site; for this site, with re-
spect to “start1”, the TCR was shifted by 20 Å along the
MHC-like helix axis toward the α1 helix C-term, rotated
to a 0° crossing angle, and tilted by 25° toward the
MHC-like helix axis C-term. Additional “start3” and
“start4” sites included 10 Å and 25 Å TCR shifts, cross-
ing angles of 22.5° and −15°, and tilts of 12.5° and 40°,
respectively.
Evaluation of docking models
Docking models were evaluated using CAPRI criteria to
assess predictions as “incorrect”, “acceptable”, “medium
accuracy” and “high accuracy” [21]. As with our previous
TCR docking study, models assessed as medium or high
accuracy are referred to as hits. Lipid and metabolite
antigen atoms were included in calculation of bound
contacts with TCR residues, but were omitted from
RMSD calculations (only protein backbone atoms were
used).
Retraining ZRANK scoring function
As for the original ZRANK implementation [36], we
employed a downhill simplex to select weights for the
terms of the ZRANK scoring function, in this case maxi-
mizing the average area under the receiver operating
characteristic curve (AUC) of 20 TCR-pMHC docking
test cases [11], distinguishing hit from non-hit predic-
tions among the top 30 ranked models for each TCR-
pMHC case. To avoid local minima, the downhill sim-
plex was run from 12,000 randomly generated starting
points. For three-fold cross-validation within the TCR-
pMHC set, training and testing sets were selected such
that cases with the same TCR were not used simultan-
eously in both sets. The retrained scoring function
weights (and ZR2 weight values [22] in parentheses, for
comparison) used to select TCR docking models are:
van der Waals attractive: 0.027 (1.0)
van der Waals repulsive: 1.33 (0.23)
Electrostatics short-range attractive: 0.35 (0.57)
Electrostatics short-range repulsive: 0.29 (0.56)
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Electrostatics long-range attractive: 0.30 (1.09)
Electrostatics long-range repulsive: 0.21 (0.29)
ACE: 0.64 (0.7)
IFACE: 0.27 (0.38)
Figures
Plots were generated using gnuplot (www.gnuplot.info),
and molecular visualizations were produced using PyMOL
(www.pymol.org). Clustering and generation of the
unrooted tree were performed using the APE package [37]
in R (www.r-project.org).
Additional files
Additional file 1: Figure S1. Receptor interface RMSD versus ligand
RMSD for test cases 4EI5 and 4LHU.
Additional file 2: Figure S2. Top-ranked ZRT model for test case 4EI5,
showing (A) complex and (B) α chain interface with CD1d-Ag. CD1d is
green, crystal structure TCR α and β chains are slate and tan, predicted
TCR α and β chains are orange and blue, unbound Ag is magenta, bound
Ag is cyan, and predicted Ag is yellow.
Additional file 3: Table S1. Docking performance when initiated from
the “start2” site.
Additional file 4: Figure S3. ZRT score versus interface RMSD for
docking test cases. Red circles represent models from the “start1” docking
start site, while blue triangles represent models from the “start2” docking
start site.
Additional file 5: Figure S4. ZRT score versus interface RMSD for
docking test case 4LHU, using four docking start positions. Docking start
sites shown are “start1” (red circles), “start2” (blue triangles), “start3”
(magenta triangles), and “start4” (cyan circles).
Additional file 6: Figure S5. Distances between top 20 models (ranked
by ZRT score) of Clone 18 GEM TCR (4G8E) bound to CD1b-MA and
models of Clone 42 GEM TCR (4G8F) bound to CD1b-GMM, calculated using
shared (identical in sequence) CDR1α and CDR2α loops. The lowest RMSD
among all pairs of models (1.37 Å) is boxed, and corresponds to the
predictions selected for further analysis (4G8E model 3 and 4G8F model 12).
Additional file 7: Figure S6. RMSD-based clustering of the top 20
4G8E and 4G8F models bound to CD1b-Ag. Selected sets of models are
circled to indicate similarity with existing TCR complex crystal structures
based on comparison of variable domain orientations after superposition
of MHC or MHC-like structures.
Additional file 8: Figure S7. Additional GEM TCR-CD1b-Ag models
compared with TCR-pMHC structures. Shown are (A) 4G8E-CD1b-MA
model 18 and 1G4 TCR-HLA-A2-peptide (PDB code 2BNR), and (B) 4G8F-
CD1b-GMM model 5 and TRBV6 MAIT TCR-MR1-6FP CD1b-Ag (PDB code
4L4V). Colors are: GEM TCR α chains, blue; GEM TCR β chains, salmon;
crystallographic α chain, cyan; crystallographic β chain, yellow; CD1b/
MR1/MHC, green; antigens, magenta.
Additional file 9: Figure S8. ZRT score versus interface RMSD for the
4L4T test case models (from the original “start1” docking position)
evaluated against the recently released crystal structure of the same MAIT
TCR in complex with a distinct Ag and MR1 (PDB code 4PJ8).
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